Osimertinib has become the reference treatment for EGFR-mutated non-small cell lung cancer (NSCLC), and hospital pharmacies, oncology centres and chemists across India now field the same questions again and again: which osimertinib 80 mg brands are in the market, how do they differ, and how can a buyer confirm that stock is genuine and correctly handled? This guide answers those questions from a distributor’s point of view. It is written for procurement teams, hospital pharmacists and oncology clinics, not for patients, and it does not replace the prescribing information or an oncologist’s judgement.